CTLA-4 blockade stimulates anti-tumor immunity by increasing the expansion of CD45RO+ICOS+PD-1lowTBET+ Th1-like CD4+ effector and also exhausted-like CD8+ T cells (240). The gene discussed is CD4; the disease is neoplasm.